Social Media Ideas for Citius Pharmaceuticals

Citius Oncology of Cranford says commercial response to cancer treatment is strong

Citius Oncology Inc., an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals Inc., provided an update Aug. 5 on the expanding base of...

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

<![CDATA[The Status of Nuvation Bio’s Pipeline]]>

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the firs...

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the pub...

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Wed, 07/29/2026 - 18:25 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

<![CDATA[Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics for alvelestat ]]>

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

Celcuity plans late Q3 2026 REVTORPYK shipments and targets sNDA submission in Q3 2026

Pain drugmaker Latigo outlines plans to go public

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug

Sentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.

<![CDATA[Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement ]]>

<![CDATA[Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals ]]>

<![CDATA[Aptar and Aceso Therapeutics Enter Collaboration for Cystic Fibrosis Therapy ]]>

Citius Oncology appoints independent director Peri to board of directors

Citius Oncology, Inc., an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc., announced that its board of directors voted to a...

<![CDATA[Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Se...

<![CDATA[M&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Ent...

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in pr...

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

<![CDATA[Pharmaceutical Executive Daily: Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutic...

Calliditas?

Calliditas? Anonymous (not verified) Wed, 08/12/2026 - 00:32 field_thread_url https://cafepharma.com/boards/threads/calliditas.661472/ b...

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve...

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...